ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients

M. Chunduru, K. Schnelle, H. Winters, O. Witkowsky, L. Von Stein

The Ohio State Wexner Medical Center, Columbus, OH

Meeting: 2020 American Transplant Congress

Abstract number: C-201

Keywords: Drug interaction, Hepatitis C, Viral therapy

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session C: Non-Organ Specific: Viral Hepatitis

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
  • Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study

*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased tacrolimus concentrations due to known strong inhibition of CYP3A4. GP is noted to be a weak inhibitor of CYP3A4, but insufficient data exist regarding its impact on tacrolimus troughs. This study describes the effect of GP on tacrolimus troughs in abdominal transplant recipients.

*Methods: A retrospective analysis of liver and/or kidney patients transplanted between November 2017 and July 2019 receiving GP post-transplant was conducted. Patients were excluded if they had not completed 12 weeks of therapy with GP. Tacrolimus troughs were collected prior to and during GP administration per institution lab protocol.

*Results: Fourteen recipients were included in this analysis: kidney (n=5, 35.7%), liver (n=8, 57.1%), simultaneous liver and kidney (n=1, 7.1%). Time to GP initiation was a mean of 153 days (SD +/- 100.4) post-transplant. The majority of patients had hepatitis C prior to transplant while others received a hepatitis C nucleic acid test positive organ (64.3% versus 35.7%). Figure 1 shows the weekly mean dose normalized tacrolimus trough concentrations of recipients prior to GP initiation and during GP therapy. The mean percent change in dose normalized tacrolimus troughs (ng/ml/dose) after GP initiation was an increase of 24% in kidney alone transplant recipients and 61% in liver transplant recipients. With regard to tacrolimus dose adjustments, kidney alone recipients had a mean decrease of 15%, while liver recipients had a mean decrease of 28%. Of note, 2 of 5 kidney alone recipients and 3 of 9 liver recipients had no dose changes. Eleven patients (4 kidney alone recipients and 7 liver recipients) had supratherapeutic tacrolimus (>10ng/ml) troughs while on GP. Of these patients, 2 kidney alone recipients also had supratherapeutic levels immediately prior to initiation of GP.

*Conclusions: Based on these data, using glecaprevir-pibrentasvir without preemptive dose adjustment of tacrolimus is reasonable in kidney and liver transplant recipients, but close tacrolimus therapeutic drug monitoring should be performed while on GP. A larger study may help guide the timing and extent of dose adjustment of tacrolimus in abdominal transplant recipients.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chunduru M, Schnelle K, Winters H, Witkowsky O, Stein LVon. Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/glecaprevir-pibrentasvir-effect-on-tacrolimus-troughs-in-abdominal-transplant-recipients/. Accessed March 9, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.